What is BMY's health score?

BRISTOL MYERS SQUIBB CO (BMY) has a TradeApes health score of 62 out of 100, rated Healthy. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is BMY's estimated fair value?

Based on our 5-year discounted cash flow model, BRISTOL MYERS SQUIBB CO's estimated fair value is $74.25 per share, representing a 22.2% upside from the current price. This is a model estimate, not a price target or investment recommendation.

Is BMY undervalued or overvalued?

Our model currently rates BMY as Undervalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

To Unlock Full Report

2 free score cards remaining

BRISTOL MYERS SQUIBB CO (BMY)

Healthcare Undervalued high healthy

$60.74

Updated: 2026-07-18

TradeApes Score

Financial Strength

60 Healthy

Operating Trend

50 Mixed

Relative Value

65 Healthy

Capital Allocation

65 Healthy

Risk Management

80 Strong

Est. Fair Value $74.25

DCF Upside +22.2%

Sector Rank #8462 of 12113

Key Findings

+ High FCF yield — above 7%, strong cash return relative to price paid

Unlock Full Report →

Industry Related Stocks

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Aardvark Therapeutics, Inc. (AARD) Abivax S.A. (AAVXF) Ascend Wellness Holdings, Inc. (AAWH) AbbVie Inc. (ABBV) AbCellera Biologics Inc. (ABCL)

See all Healthcare stocks →

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.